a combination of long-acting amylin analog cagrilintide and GLP-1 agonist semaglutide. The Big Pharma is currently testing the obesity treatment out in phase 3 trials, with a readout expected ...
(Bloomberg) -- Novo Nordisk A/S’s appetite-blocking shot semaglutide, sold under the ... The key to the new combination is a ...